維亞生物(01873.HK):正與朗華製藥討論潛在戰略投資及合作
格隆匯12月27日丨維亞生物(01873.HK)發佈公告,公司現正與浙江朗華製藥有限公司(“朗華製藥”)討論關於全球醫藥市場的研究、開發、設計和生產領域的潛在戰略投資及合作。
朗華製藥是一家位於浙江省化學原料藥基地臨海園區,2018財政年度收入超過10億元人民幣,淨利潤近1億元人民幣的綜合性藥品研發生產平台。朗華製藥已獲得美國FDA、歐盟EDQM、世界衞生組織WHO官方認證,並通過PSCI審計,努力成為客户優選的合同研發定製(CDMO)夥伴。於該公告日期,集團尚未就潛在戰略投資及合作訂立任何最終協定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.